Altimmune, Inc. (ALT) stock
Close on Nov 11, 2026Market cap $375.42MP/E –Yield –
Altimmune, Inc. grew revenue 105.0% to $41.00K over fiscal 2025. Free cash flow was -$76.56M. At the latest close the market valued the company at $375.42M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $375.42M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.79
- Dividend yield
- –
- Free cash flow yield
- -20.39%
Fundamentals
- Revenue
- $41.00K
- Net income
- -$91.76M
- EPS, diluted
- -$0.77
- Free cash flow
- -$76.56M
- Book value per share
- $2.56
- Diluted shares
- 185M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.94
- Open
- $1.95
- Day's range
- $1.90 – $1.99
- Volume
- 2,939,814
- Average volume (20 days)
- 3,430,858
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.09
- 52-week range
- $1.90 – $6.44
- RSI (14 days)
- 32.7
- Volatility (1 year)
- 69.9%
- Relative volume
- 0.73×
- WACC
- 10.2%
On 3 of our idea lists: More cash than they're worth, Institutions accumulating, Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALT | S&P 500 | Difference | ALT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -26.1% | -2.4% | −23.6 pts | ||
| 3 months | -35.7% | -1.2% | −34.5 pts | ||
| Year to date | -46.5% | +12.3% | −58.8 pts | ||
| 1 year | -54.9% | +12.4% | −67.4 pts | ||
| 3 years | -22.8% | +78.8% | −101.6 pts | -8.3% | +21.4% |
| 5 years | -82.6% | +75.2% | −157.7 pts | -29.5% | +11.9% |
| 10 years | -99.8% | +311.1% | −410.9 pts | -45.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Altimmune filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Results
About Altimmune
Pharmaceutical Preparations
Altimmune, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic treatments for severe liver conditions. Its primary product candidate is pemvidutide, an investigational dual receptor agonist targeting metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company focuses entirely on clinical research and development without commercial operating segments. Because its therapies are still undergoing clinical evaluation, the company has no commercial customers; its treatments are intended for patients suffering from metabolic and alcohol-related liver diseases.
Company profile, executives and historyAltimmune stock: common questions
What is Altimmune's stock price?
ALT closed at $1.93 on Nov 11, 2026, down 0.52% on the day. Over the past 52 weeks it traded between $1.90 and $6.44.
What is Altimmune's market cap?
Altimmune was worth $375.42M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ALT's P/E ratio?
Altimmune lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.77), so it has no meaningful P/E ratio.
How much revenue does Altimmune make?
Altimmune reported revenue of $41.00K for fiscal 2025, up 105.0% from a year earlier.
Does Altimmune pay a dividend?
No. Altimmune has not paid a cash dividend over the last twelve months.
When does Altimmune report earnings next?
Altimmune's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has ALT stock performed over the past year?
Including dividends, ALT returned -54.9% over the past year, against +12.4% for the S&P 500.
How many ALT shares are sold short?
42M shares were sold short at the latest FINRA report, 21.77% of the float, or 12.2 days of average trading volume.
Who are Altimmune's competitors?
Companies most similar to Altimmune by business, industry and size include AVTX, NTHI, ADXN, KZIA, IXHL.
See a number that looks wrong?